Invasive Mold Infections After Chimeric Antigen Receptor–Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis-Reference-Cited by-同舟云学术

Invasive Mold Infections After Chimeric Antigen Receptor–Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis

Published:2019-11-22 Issue:3 Volume:71 Page:672-676
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Haidar Ghady¹²,Dorritie Kathleen¹³,Farah Rafic³,Bogdanovich Tatiana²,Nguyen M Hong¹²,Samanta Palash²

Affiliation:

1. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

2. Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

3. Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

Abstract

Abstract Data on invasive mold infections (IMIs) after chimeric antigen receptor-modified T-cell (CAR-T-cell) therapy are limited. We describe 2 patients with post–CAR-T-cell IMI (Fusarium, Mucorales) and review the published literature. We propose strategies to prevent IMIs in patients, based on the IMI rate and presence of neutropenia or steroid use.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciz1127/32980445/ciz1127.pdf

Reference16 articles.

1. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy;Mahadeo;Nat Rev Clin Oncol,2019

2. Early and late hematologic toxicity following CD19 CAR-T cells;Fried;Bone Marrow Transplant,2019

3. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy;Hill;Blood,2018

4. Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-Cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells;Park;Clin Infect Dis,2018

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of infectious complications among CAR T- cell therapy recipients;Frontiers in Oncology;2024-07-03

2. Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies;Transplantation and Cellular Therapy;2024-07

3. Infections associated with CAR‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies;Cancer Medicine;2024-06

4. Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy;Clinical Hematology International;2024-04-29

5. Patients with aggressive B‐cell lymphoma receiving CAR T‐cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis;European Journal of Haematology;2024-04-26